BUSINESS

Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist

January 20, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Pollen allergy approval for Novartis’ asthma drug Xolair (omalizumab) last year caused quite a stir over its potential impact on health finances in Japan, but a specialist says its actual use for the new indication would be limited to 1-3%…

To read the full story

Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
Xolair Adds Pollen Allergy Use in Japan after 19-Day Delay
December 12, 2019

BUSINESS

Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
Meiji Launches Rezurock in Thailand
April 3, 2026
Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing

By Sakura Kono

Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…

COLUMN

Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing

By Philip Carrigan

Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…